Leucid Bio Raises £11.5M In Series A Financing To Develop Next Generation Of Innovative Chimeric Antigen Receptor T Cell (Car-T) Therapies
Amount Raised
£11.5 Million
Round Type
Series A
LondonBiotechnologyHealth CareDescription
Leucid Bio ("Leucid" or the "Company"), a biotech company pioneering next-generation cell therapies for hard-to-treat cancers, today announces that it has successfully raised £11.5 million in a Series A financing round. The investment was led by Epidarex and new investor Vulpes Investment Management, with participation from new investors 2Invest and Future Fund of the British Business Bank, and existing investor Sofinnova Partners. Proceeds from the financing will be used to initiate a Phase 1 trial of its lead candidate, LEU-011, for the treatment of platinum resistant ovarian cancer.
Quick answer
Leucid Bio raised £11.5 Million in a Series A round, dated October 21, 2021. Leucid Bio is based in London, England, United Kingdom.
- How much did Leucid Bio raise?
- Leucid Bio raised £11.5 Million in a Series A round on October 21, 2021.
- What does Leucid Bio do?
- Leucid is progressing novel CAR T therapies that produce a better and more durable response than previous CAR T generations, improving treatment outcomes and saving the lives of patients with refractory cancers.
- Where is Leucid Bio based and how big is it?
- Leucid Bio is based in London, England, United Kingdom.
- Who are the decision-makers at Leucid Bio?
- Fundz holds 1 contact at Leucid Bio. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Biotechnology and Health Care around the same time
Companies in the same sectors as Leucid Bio that raised within 45 days of this round, from Fundz verified event records.
- BioLumic raised $1.3M (Seed) on December 3, 2021.
- Petros Pharmaceuticals, Inc. raised $3.5M (Seed) on December 3, 2021.
- CytoDyn raised $11M on December 3, 2021.
- Amarna Therapeutics raised $5.4M (Funding Round) on December 1, 2021.
- medimaps group S.A raised $20M (Funding Round) on December 1, 2021.
- MedinCell raised $4.3M (Seed) on December 1, 2021.
Who to call at Leucid Bio, and when
A new round usually means Leucid Bio is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Leucid Bio raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Leucid Bio, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Leucid Bio. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Leucid Bio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansLeucid Bio raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.